# Displaying PRO Results Graphically: Applying the Recommendations



#### Claire Snyder, PhD and Michael Brundage, MD, MSc Principal Investigators






PROTEUS Patient-Reported Outcomes Tools: Engaging Users and Stakeholders


Funded by the Patient-Centered Outcomes Research Institute and Genentech

### **Overview of Presentations**

TheProteusConsortium.org




# **Displaying PRO Results Graphically**





### **Displaying PRO Results Graphically**



To promote consistent presentation of PRO data so that clinicians and patients can understand what PRO scores mean

Provides evidence-based recommendations for presenting PRO data clearly to patients and clinicians/researchers



# **Displaying PRO Results Graphically**

Quality of Life Research https://doi.org/10.1007/s11136-018-2020-3



# Making a picture worth a thousand numbers: recommendations for graphically displaying patient-reported outcomes data

Claire Snyder<sup>1,2,3</sup> · Katherine Smith<sup>2,3</sup> · Bernhard Holzner<sup>4</sup> · Yonaira M. Rivera<sup>2</sup> · Elissa Bantug<sup>3</sup> · Michael Brundage<sup>5</sup> · PRO Data Presentation Delphi Panel

Accepted: 29 September 2018 © Springer Nature Switzerland AG 2018

Snyder et al, Qual Life Res 2019, 28(2), 345-356



### **Acknowledgements**

#### **PROJECT TEAM**

Claire Snyder, PhD Michael Brundage, MD, MSc Elissa Bantug, MHS Katherine Smith, PhD Bernhard Holzner, PhD

#### STAKEHOLDER ADVISORY BOARD

Daniel Weber Ethan Basch, MD Neil Aaronson, PhD Bryce Reeve, PhD Galina Velikova, BMBS(MD), PhD Andrea Heckert, PhD, MPH Eden Stotsky-Himelfarb Cynthia Chauhan Vanessa Hoffman, MPH Patricia Ganz, MD Lisa Barbera, MD, MPA

#### **INVITED PARTICIPANTS**


Elizabeth Frank Mary Lou Smith, JD Arturo Durazo Judy Needham Shelley Fuld Nasso Robert Miller, MD Tenbroeck Smith, MA Deborah Struth, MSN, RN, PhD(c) Alison Rein, MS Andre Dias, PhD Charlotte Roberts, MBBS, BSc Nancy Smider, PhD Gena Cook Jakob Bjorner, MD, PhD Holly Witteman, PhD James G. Dolan, MD Jane Blazeby, MD, MSc Robert M. Golub, MD Christine Laine, MD, MPH Scott Ramsev, MD, PhD



**Funded** by the Patient-Centered Outcomes Research Institute

# Why Is This Resource Needed?

 Both patients and clinicians endorse the value of PROs, but also report challenges interpreting the meaning and implications of PRO data





# Why Is This Resource Needed?

Barriers to interpreting PRO data include variation in:

- PRO instruments
  - Over 800 listed in PROOLID database (http://proqolid.org/)
- Scoring
  - Higher scores may be better or worse
- Scaling
  - $_{\circ}~$  E.g. 0-100 vs. normed to 50
- Presentation
  - $_{\circ}~$  E.g. mean scores vs responders/ graphic vs. tabular



### Why Is This Resource Needed?

- Variations in how PRO measures are scored and scaled, and in how the data are reported, make interpretation difficult and limit patients' and clinicians' use of the data in clinical practice
- Clear and standardized graphical presentation of PRO data has the potential to:
  - promote meaningful interpretation of PRO data
  - o facilitate their use in practice



### **Objective of Resource**


To provide evidence-based recommendations for PRO data display to facilitate ease of interpretation for presenting results to:

- Patients (i.e. educational materials and decision aids)
- Clinicians/researchers (i.e. peer-reviewed publications)

[Also addresses display for individual patient data, though not covered here]



#### **Methods: Modified-Delphi Process**



PROTEUS

#### **Parameters for recommendations**

- Should work on paper (static presentation)
- Presentation in color is possible (but should be interpretable in grayscale)
- Additional functionality in electronic presentation is possible (but not part of standards)


#### **Recommendations:**

# Research results presented to patients (i.e. educational materials and decision aids)



#### **Research Results Presented to Patients**

**Patients' Functioning** 






# **Directionality of PRO Scores**

- There is no easy solution to the issue of directionality. There is a split in the "intuitive" interpretation of symptom scores, with some people expecting that higher scores would be "better" and others expecting that higher scores would be "more" of the symptom (and, therefore, worse)
- The Consensus Panel warned against trying to change current instruments even if only how the data are displayed (e.g., "flipping the axes" where required for symptom scores so that lines going up are always better)
- PRO data presentation should avoid mixing score direction in a single display
- Mixed directionality between domains can cause confusion for both clinicians and patients. There is a need to address this potential confusion by using exceptionally clear labeling, titling, and other annotations






#### PROTEUS


# **Conveying Score Meaning**

- Descriptive labels (e.g., none/mild/moderate/severe) along the y-axis are helpful and should be used when data supporting their location on the scale are available
- At a minimum, anchors for the extremes should be included (e.g., none/severe), as these labels also help with the interpretation of directionality. Labels for the middle categories (e.g., mild/moderate) should be included if evidence is available to support the relevant score ranges for each label
- In addition to the descriptive y-axis labels, reference values for comparison populations should be included if they are available





#### **Patients' Symptoms**



#### PROTEUS


# **Normed Scoring**

- PRO data presentation needs to accommodate instruments the way they were developed, with or without normed scoring
- One can decide if/when to show the reference population norm visually (with a line on the graph), understanding that displaying it might provide additional interpretive value, but potentially at the cost of greater complexity
- Comparison to the norm might be less relevant in the context where the primary focus is the choice between treatments

If a norm is displayed:

- 1. It is necessary to describe the reference population and label the norm as clearly as possible (recommend "average" rather than "norm")
- 2. It also requires deciding what reference population to show (to the extent that options are available)
- 3. It will need to be explained to patients that this normed population may not be applicable to a given patient





### **Clinically Important Differences**

• Patients may find information regarding clinically important differences between treatments to be confusing, but it is important for them to know what differences "matter" if they are going to make an informed decision




### **Proportions changed**

• Pie charts are the preferred format for displaying proportion meeting a responder definition (improved, stable, worsened), so long as the proportion is also indicated numerically



#### Status of 100 patients 9 months after starting treatment




#### **Recommendations:**

#### Research results presented to clinicians (i.e. peerreviewed publications)



#### **Research Results Presented to Clinicians**

**Patients' Functioning** 




**Legend:** For all graphs, *p*-values are for between-treatment differences over time, and vertical lines indicate 95% confidence limits at each time point. † indicates differences between treatments that are clinically important.

PROTEUS

### **Directionality of PRO Scores**

- The Consensus Panel acknowledges the challenges associated with directionality. There is a split in the "intuitive" interpretation of symptom scores, with some people expecting that higher scores would be "better" and others expecting that higher scores would be "more" of the symptom (and, therefore, worse)
- The Consensus Panel recommends against changing the scoring of current instruments
- PRO data presentation should avoid mixing score direction in a single display. In cases where this is not possible, authors should consider changing the directionality in the display to be consistent
- There is a need for exceptionally clear labeling, titling, and other annotations






# **Conveying Score Meaning**

- Descriptive labels (e.g., none/mild/moderate/severe) along the y-axis are helpful and should be used when data supporting their location on the scale are available
- In addition to the descriptive y-axis labels, reference values for comparison populations should be considered for inclusion if they are available





PROTEUS


# **Normed Scoring**

- PRO data presentation needs to accommodate instruments the way they were developed, with or without normed scoring
- One can decide if/when to show the reference population norm visually (e.g., with a line on the graph), understanding that displaying it might provide additional interpretive value, but potentially at the cost of greater complexity
- Display of the norm might be less relevant in the context where the primary focus is the choice between treatments

If a norm is displayed:

- 1. It is necessary to describe the reference population and label the norm as clearly as possible (recommend "average" rather than "norm")
- 2. It also requires deciding what reference population to show (to the extent that options are available)






<sup>†</sup> indicates differences between treatments that are clinically important.



### **Clinical Importance**

- Clinically important differences between treatments should be indicated with a symbol of some sort (described in a legend). The use of an asterisk is not recommended (as it is often used to indicate statistical significance)
- If there is no defined clinically important difference, that also needs to be in the legend and/or the text of the paper








### **Statistical** Significance

- The data suggest that clinicians and others appreciate p-values; however, the Consensus Panel recognizes a move away from reporting them (and toward the use of confidence limits to illustrate statistical significance)
- Regardless of whether p-values are reported, confidence intervals should always be displayed








### **Proportions Changed**


- Responder analysis results should be displayed visually
- Reasonable options include bar charts, pie charts, or stacked bar charts



#### Status of 100 patients 9 months after starting treatment



#### Status of 100 patients 9 months after starting treatment



annotated on each slice so stacked proportions can be

No horizontal line separating domains since directionality not relevant with proportions

> Legend replicated for easy access and order is the same as stacked bar sections

# Key Differences Between Recommendations for Patients vs Clinicians/Researchers

#### **Directionality (for clinicians and researchers only)**

• If it is not possible to avoid mixing score direction in a single display, authors may consider changing the directionality in the PRO data display to be consistent in journal publications

#### Normed scoring (for patients only)

• If a norm is displayed it will need to be explained to patients that this normed population may not be applicable to a given patient

#### Conveying clinical and statistical significance (for clinicians and researchers only)

- A symbol should be used to indicate clinically important differences between treatments
- Confidence intervals should be displayed
- P-values may also be appreciated

#### **Proportions changed**

- Pie charts are preferred for patients
- Bar charts, pie charts, or stacked bar charts are reasonable options for clinicians and researchers
  PROTEL

### Recap

- PRO data have enormous potential to promote patient-centered care, but for this potential to be realized, clinicians and patients need to be able to understand what PRO scores mean
- To address this, a modified Delphi consensus process was conducted with a broad range of key stakeholders to develop recommendations for PRO data display
- The consensus process produced clear guidance for PRO data display to promote patient-centered care by optimizing accurate and meaningful interpretation of PRO results



# **Further Reading**

Brundage M, Smith K, Little E et al. Communicating patient-reported outcome scores using graphic formats: Results from a mixed methods evaluation. *Quality of Life Research*.24;2457-2472; 2015.

Bantug E, Coles T, Smith K et al. Graphical displays of patient-reported outcomes (PRO) for use in clinical practice: What makes a PRO picture worth a thousand words? *Patient Education and Counselling.* 99;483-490; 2016.

Smith K, Brundage M, Tolbert E et al. Engaging stakeholders to improve presentation of patient-reported outcomes data in clinical practice. *Support Care Cancer.* 4149-4157; 2016.

Brundage M, Blackford A, Tolbert E et al. Presenting comparative study PRO results to clinicians and researchers: Beyond the eye of the beholder. *Quality of Life Research*. 27:75-90; 2018.

Tolbert E, Brundage M, Bantug E, Blackford AL, Smith K, Snyder C; PRO Data Presentation Stakeholder Advisory Board. Picture this: Presenting longitudinal patient-reported outcome research study results to patients. *Medical Decision Making*.38:994-1005;2018.

Tolbert E, Brundage M, Bantug E, Blackford AL, Smith K, Snyder C; PRO Data Presentation Stakeholder Advisory Board. In proportion: Approaches for displaying patient-reported outcome research study results as percentages responding to treatment. *Quality of Life Research*.28:609-20;2019.

Snyder C, Smith K, Holzner B et al. Making a picture worth a thousand numbers: Recommendations for graphically displaying patient-reported outcomes data. *Quality of Life Research*.28:345-35; 2019.

